Journal of the American Heart Association · 2025
Targeting of Cdc42-Interacting Protein 4-Calcineurin Signalosomes Improves Cardiac Structure and Function After Myocardial Infarction.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Samuelsson Anne-Maj, Bayer Abraham L, Li Jinliang, Li Yang, Lewis DeEsmond, Turcotte Moriah G, Dodge-Kafka Kimberly L, Alcaide Pilar, Kapiloff Michael S
Аннотация
BACKGROUND: CaN (calcineurin) promotes pathological cardiac remodeling but also cardioprotection in ischemia-reperfusion injury. CaN inhibitors are also immunosuppressants. This pleiotropy complicates targeting calcineurin in cardiovascular disease. CIP4/TRIP10 (Cdc42-interacting protein 4) is a scaffold protein that binds the CaNAβ (calcineurin Aβ) N-terminal polyproline domain and organizes a calcium and CaNAβ2 signaling compartment independent of contractile calcium. We showed that CIP4-CaNAβ2 signalosomes promote pathological cardiac hypertrophy induced by pressure overload. It is unknown whether CIP4-CaNAβ2 signalosomes contribute to cardioprotection and remodeling in ischemic disease.
METHODS: CIP4 conditional knockout mice were studied following ischemia-reperfusion and permanent left coronary artery ligation that induce myocardial infarction. C57BL/6NJ mice were transduced with cardiotropic adeno-associated virus expressing a CaNAβ2 small hairpin RNA to inhibit CaNAβ2 expression, a VIVIT peptide to inhibit CaN-NFAT (nuclear factor of activated T cells) signaling, or a CaNAβ polyproline peptide to block CIP4-CaNAβ2 binding and similarly studied by ischemia-reperfusion injury and left coronary artery ligation. CaNAβ polyproline-dependent signaling was also studied in T cells.
RESULTS: CIP4 conditional knockout and cardiomyocyte-specific CaNAβ polyproline peptide expression improved cardiac function after ischemia-reperfusion injury and decreased infarct size and improved cardiac function after permanent left coronary artery ligation. In contrast, cardiomyocyte-specific CaNAβ2 depletion and VIVIT expression worsened outcome after myocardial infarction. The polyproline peptide had no effect on T-cell activation and cytokine expression in vitro.
CONCLUSIONS: CIP4-CaNAβ2 signalosomes promote adverse cardiac remodeling and are not cardioprotective. Proof of concept is provided for the treatment of ischemic cardiomyopathy by a polyproline peptide gene therapy. Targeting these complexes may be beneficial in cardiovascular diseases, including ischemic cardiomyopathy and acute myocardial infarction.
METHODS: CIP4 conditional knockout mice were studied following ischemia-reperfusion and permanent left coronary artery ligation that induce myocardial infarction. C57BL/6NJ mice were transduced with cardiotropic adeno-associated virus expressing a CaNAβ2 small hairpin RNA to inhibit CaNAβ2 expression, a VIVIT peptide to inhibit CaN-NFAT (nuclear factor of activated T cells) signaling, or a CaNAβ polyproline peptide to block CIP4-CaNAβ2 binding and similarly studied by ischemia-reperfusion injury and left coronary artery ligation. CaNAβ polyproline-dependent signaling was also studied in T cells.
RESULTS: CIP4 conditional knockout and cardiomyocyte-specific CaNAβ polyproline peptide expression improved cardiac function after ischemia-reperfusion injury and decreased infarct size and improved cardiac function after permanent left coronary artery ligation. In contrast, cardiomyocyte-specific CaNAβ2 depletion and VIVIT expression worsened outcome after myocardial infarction. The polyproline peptide had no effect on T-cell activation and cytokine expression in vitro.
CONCLUSIONS: CIP4-CaNAβ2 signalosomes promote adverse cardiac remodeling and are not cardioprotective. Proof of concept is provided for the treatment of ischemic cardiomyopathy by a polyproline peptide gene therapy. Targeting these complexes may be beneficial in cardiovascular diseases, including ischemic cardiomyopathy and acute myocardial infarction.